|
T12268 |
NTP42
|
|
Prostaglandin Receptor
,
PPAR
|
|
NTP42 is an antagonist of thromboxane A2 (TXA2) receptor(IC50 of 3.278 nM) |
|
T11339 |
Furegrelate sodium
|
U-63557A |
PPAR
|
|
|
|
T8900 |
Seralutinib
|
GB002 |
PDGFR
|
|
Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension. |
|
T2561 |
Macitentan
|
ACT-064992 |
Apoptosis
,
Endothelin Receptor
|
|
Macitentan (ACT-064992) is an endothelin receptor antagonist that is used in the therapy of pulmonary arterial hypertension (PAH). |
|
T5329 |
Trandolapril
|
|
Angiotensin-converting Enzyme (ACE)
|
|
Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that is hydrolysed to the active diacid trandolaprilat. |
|
T14782 |
Brilaroxazine
|
RP5063 |
Dopamine Receptor
,
5-HT Receptor
|
|
Brilaroxazine (RP5063) is a potent multimodal dopamine/5-HT modulator. Brilaroxazine is a partial agonist of dopamine D2, D3, and D4 receptors, 5-HT1A (Ki =1.5 nM) and 5-HT2A (Ki = 2.5 nM), and has antagonist activity 5-... |
|
T11339L |
Furegrelate
|
|
PPAR
|
|
FUREGRELATE, a thromboxane A2 (TxA2) synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. |
|
T26841 |
BMS 182874
|
BMS182874,BMS-182874 |
Endothelin Receptor
|
|
BMS 182874 is an orally effective and highly selective endothelin receptor ETA antagonist with an IC50 value of 0.150 μM for ETA and a Ki value of 0.055 μM for ETA.BMS 182874 is able to reduce arterial pressure in a rat ... |
|
T3216 |
Selexipag
|
NS-304,ACT-293987,Uptravi |
Others
,
Prostaglandin Receptor
|
|
Selexipag (ACT-293987)(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH). |
|
T6968 |
Riociguat
|
BAY 632521 |
Guanylate cyclase
|
|
Riociguat (BAY 632521) is a stimulator of guanylate cyclase which causes relaxation of vascular smooth muscle and is used to treat severe pulmonary arterial hypertension. |
|
T1655 |
Ambrisentan
|
BSF-208075,BSF 208075,LU 208075 |
Endothelin Receptor
|
|
Ambrisentan (BSF 208075) is an endothelin receptor antagonist used in the therapy of pulmonary arterial hypertension (PAH). Ambrisentan has been associated with a low rate of serum enzyme elevations during therapy but ha... |
|
T36008 |
Nebentan potassium
|
YM598 |
Endothelin Receptor
|
|
Nebentan potassium (YM598) is an orally active and selective nonpeptide endothelin receptor (ETA receptor) antagonist.Nebentan potassium inhibits pulmonary arterial hypertension and may be useful in the study of neurolog... |
|
T6264 |
Bosentan
|
Actelion,Ro 47-0203,Benzenesulfonamide |
Endothelin Receptor
|
|
Bosentan (Benzenesulfonamide) is a sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks th... |
|
T27624 |
Iptakalim Hydrochloride
|
|
Potassium Channel
,
AChR
|
|
Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist. Iptakalim is also a K(ir) 6.1/SUR2... |
|
T13193 |
TPN171
|
|
PDE
|
|
TPN171 is potent PDE5 inhibitor with subnanomolar potency for PDE5 and good selectivity over PDE6, which has the potential for the treatment of pulmonary arterial hypertension (PAH). TPN171 was proven to exert a longer l... |
|
T19660 |
QCC-374
|
QCC374 |
|
|
QCC-374 is a prostanoid agonist. It potentially for the treatment of pulmonary arterial hypertension. |
|
T30501 |
BMS-193884
|
BMS193884,BMS 193884 |
|
|
BMS-193884 is an oral endothelin antagonist for the treatment of congestive heart failure (CHF) and pulmonary arterial hypertension. |
|
T0112L |
Diltiazem
|
Diltiazem free base,Dilticard,CRD-401,CRD401,Dilzen,CRD 401 |
|
|
Diltiazem is a non-dihydropyridine (non-DHP) calcium channel blocker that relaxes the smooth muscle in arterial walls, thus opening (dilating) arteries, allowing easier blood flow, and lowering blood pressure, and is use... |
|
T70704 |
RB-005
|
|
|
|
RB-005 is a potent sphingosine kinase isoform 1 (SK1) inhibitor, which may serve as therapeutic agent for proliferative diseases, including hypertension. RB-005, (IC(50) = 3.6 μM), which also induced proteasomal degradat... |
|
T11935 |
Macitentan (n-butyl analogue)
|
|
Others
|
|
Macitentan n-butyl analogue, a derivative of Macitentan, functions as an orally active dual antagonist targeting both endothelin ETA and ETB receptors. This compound shows promise for treating idiopathic pulmonary fibros... |
|
T6959 |
PRX-08066 Maleic acid
|
|
5-HT Receptor
|
|
PRX-08066 Maleic acid is a selective 5-HT2B receptor antagonist with IC50 of 3.4 nM, prevents the severity of pulmonary arterial hypertension in the MCT rat model. Phase 2. |
|
T80075 |
Cyclo(Ala-Arg-Gly-Asp-Mamb)
|
XJ735 |
Integrin
|
|
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective antagonist of the RGD peptide with potential applications in pulmonary arterial hypertension research [1]. |
|
T16779 |
Rodatristat ethyl
|
RVT-014,KAR5585,RVT-1201 |
5-HT Receptor
,
Hydroxylase
|
|
Rodatristat ethyl (KAR5585) is a first-of-its-kind orally active and potent tryptophan hydroxylase 1 (TPH1) inhibitor that significantly reduces 5-hydroxytryptamine (5-HT) levels and decreases pulmonary arterial hyperten... |
|
TP2000 |
MM 07
|
|
|
|
Apelin biased agonist; exhibits bias for the G protein pathway. Stimulates endothelial NOS phosphorylation and expression, promotes proliferation, and attenuates apoptosis of human pulmonary arterial endothelial cells in... |
|
T60429 |
SY-LB-57
|
|
|
|
SY-LB-57 is a highly effective agonist of bone morphogenetic protein (BMP) receptor signaling. SY-LB-57 can be used in studies of conditions such as bone fracture and pulmonary arterial hypertension [1]. |
|
TMIH-0520 |
Selexipag-d7
|
|
|
|
Selexipag-d7 is a deuterated compound of Selexipag. Selexipag has a CAS number of 475086-01-2. Selexipag(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the thera... |
|
T79223 |
BMPR2-IN-1
|
|
|
|
BMPR2-IN-1 (Compound 8a), is a potent inhibitor of BMPR2, exhibiting an IC50 value of 506 nM and a Kd of 83.5 nM. It is utilized in the study of various diseases including pulmonary arterial hypertension, Alzheimer's dis... |
|
T79574 |
ET receptor antagonist 2
|
|
Estrogen Receptor/ERR
|
|
ET Receptor Antagonist 2 (Compound 16j) is an orally active ET receptor antagonist with an IC50 of 0.22 nM, suitable for pulmonary arterial hypertension (PAH) research. It has been shown to mitigate monocrotaline-induced... |
|
T79573 |
ET receptor antagonist 1
|
|
Estrogen Receptor/ERR
|
|
ET Receptor Antagonist 1 (compound 16h), with an IC50 value of 0.18 nM, is an orally active agent that can be utilized for pulmonary arterial hypertension (PAH) research. It has demonstrated efficacy in mitigating monocr... |
|
T78076 |
PBR28
|
|
Others
|
|
PBR28, a TSPO modulator, holds potential for preventative research in Pulmonary Arterial Hypertension (PAH) and is instrumental in brain positron emission tomography (PET) imaging studies through its capacity for radioac... |
|
TMIH-0497 |
Riociguat-13C-d6
|
|
|
|
Riociguat-13C-d6 is the 13C and deuterated compound of Riociguat. Riociguat has a CAS number of 625115-55-1. Riociguat is a stimulator of guanylate cyclase which causes relaxation of vascular smooth muscle and is used to... |
|
T79575 |
ET receptor antagonist 3
|
|
Estrogen Receptor/ERR
|
|
"ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating ... |
|
T71065 |
Quinapril-d5
|
|
|
|
Quinapril-d5 is intended for use as an internal standard for the quantification of quinapril by GC- or LC-MS. Quinapril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor quinaprilat. In vivo, quinapr... |
|
TMIH-0519 |
Selexipag Active Metabolite-d7
|
|
|
|
Selexipag Active Metabolite-d7 is a deuterated compound of Selexipag Active Metabolite. Selexipag Active Metabolite has a CAS number of 475085-57-5. MRE-269 is an orally available and long-acting prostacyclin receptor ag... |
|
T76995 |
Sotatercept
|
|
|
|
Sotatercept (ACE-011), a soluble activin receptor type IIA (ACVR2A) IgG Fc fusion protein, aims to rebalance growth-promoting and inhibiting signaling pathways by targeting activin and growth differentiation factors. Thi... |
|
T35876 |
Chlorthalidone Impurity G
|
|
|
|
Chlorthalidone impurity G is a potential impurity found in commercial preparations of chlorthalidone that has moderate antihypertensive effects. Chlorthalidone is a thiazide-like diuretic that inhibits the Na+/Cl- cotran... |
|
T83766 |
Moexiprilat
|
RS 10029 |
|
|
Moexiprilat, an active metabolite of the prodrug moexipril formed through side chain ester hydrolysis in vivo, functions as an angiotensin-converting enzyme (ACE; IC50 = 2.1 nM) inhibitor. At a concentration of 10 nM, it... |
|
T65598 |
Cefminox sodium
|
|
|
|
Cefminox (Sodium) is a new cephamycin antibiotic possessing a D-amino acid moiety derived from D-cysteine at the C-7B side chain. Cefminox is active against a wide range of bacteria, especially Gram-negative and anaerobi... |
